X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2023/10/21/2764291/0/en/F2G-and-Shionogi-Present-Full-Data-Set-from-Pivotal-Phase-2b-Study-at-Trends-in-Medical-Mycology-TIMM-2023-Demonstrating-Positive-Therapeutic-Responses-in-Patients-with-Invasive-Fu.html
https://finance.yahoo.com/news/f2g-receives-complete-response-letter-113000837.html
https://www.pharmacompass.com/pdf/news/f2g-receives-crl-from-fda-for-nda-for-olorofim-for-the-treatment-14551.pdf
https://www.globenewswire.com/news-release/2022/12/19/2575954/0/en/F2G-Announces-FDA-Filing-Acceptance-of-New-Drug-Application-for-Olorofim-for-the-Treatment-of-Invasive-Fungal-Infections.html
https://www.globenewswire.com/news-release/2022/10/21/2539410/0/en/F2G-Announces-Data-from-Phase-2b-Study-at-ID-Week-2022-Showing-Positive-Therapeutic-Response-in-Patients-with-Invasive-Fungal-Infections-Treated-with-Olorofim.html
https://www.globenewswire.com/news-release/2022/10/13/2534044/0/en/F2G-to-Present-Interim-Results-from-Phase-2B-Open-Label-Study-of-Olorofim-in-Invasive-Fungal-Infections-at-IDWeek-2022.html
https://www.prnewswire.com/news-releases/f2g-announces-70-million-financing-to-advance-development-and-commercialization-of-new-antifungal-agent-olorofim-301599295.html
https://www.prnewswire.com/news-releases/f2g-receives-us-fda-breakthrough-therapy-designation-for-olorofim-300954815.html
Market Place
Share 
